Showing 1-10 of 17 "Breast Cancers"

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Lacey Burey

Phone: 713.441.1159

The PENELOPEB study is designed to demonstrate that in the background of standard anti-hormonal therapy palbociclib provides superior invasive disease-free survival (iDFS) compared to placebo in pre- and postmenopausal women with HR-positive/HER ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Maria Salazar

Phone: 713.441.6011

The purpose of this study is to evaluate the efficacy of enzalutamide with trastuzumab in subjects with HER2+ AR+ and ER-/PgR- metastatic or locally advanced breast cancer. ... Read more >

Status: Open Not Enrolling

Investigator: Angel Rodriguez

Study Coordinator: Maria Salazar

Phone: 713.441.6011

This open label, randomised, controlled, multi-centre phase III study will assess the efficacy and safety of single agent olaparib vs standard of care based on physician's choice of capecitabine, vinorelbine or eribulin in metastatic breast canc ... Read more >

Status: Open Not Enrolling

Investigator: Angel Rodriguez

Study Coordinator: Maria Salazar

Phone: 713.441.6011

This study will evaluate whether the addition of daily BKM120 to fulvestrant is effective and safe in treating patients with HR+, HER2-, AI treated locally advanced or metastatic breast cancer who progressed on or after mTor inhibitor based trea ... Read more >

Status: Open Not Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Erick Villarreal-Williams

Phone: 713.441.9775

The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in subjects with advanced or metastatic solid tumors who no longer respond to or have relapsed from standard therapies. ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Maria Salazar

Phone: 713.441.6011

The major purpose of this research study is to better understand how therapy works on different patients. This study is being offered to patients with a diagnosis of advanced or metastatic breast cancer who have failed anthracycline based therap ... Read more >

Status: Open Not Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the breast or axillary ... Read more >

Status: Open Not Enrolling

Investigator: Angel Rodriguez

Study Coordinator: Maria Salazar

Phone: 713.441.6011

This is a multi-center, randomized, double-blinded, placebo controlled trial in pre-menopausal women with advanced breast cancer. ... Read more >

Status: Open Not Enrolling

Investigator: Angel Rodriguez

Study Coordinator: Maria Salazar

Phone: 713.441.6011

This is a Phase 1b/2, multicenter, open-label study to evaluate the safety, tolerability, antitumor activity, and pharmacology of MEDI-573 in combination with an AI in adult subjects with HR+, HER2-negative MBC. This study has 2 phases: a dose-e ... Read more >

Status: Enrolling

Investigator: Angel Rodriguez

Study Coordinator: Maria Salazar

Phone: 713.441.6011

The main purpose of this study is to see whether CDX-011 (glembatumumab vedotin, an antibody-drug conjugate) is effective in treating patients who have advanced Triple-Negative Breast Cancer (TNBC; i.e., tumors lacking expression of estrogen, pr ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

PURPOSE: The purpose of this study is to test how effective combing a Cisplatin chemotherapy with Everolimus is in treating subjects with residual triple negative breast cancer, who have already received chemotherapy prior to surgery. </div ... Read more >

Status: Enrolling

Investigator: Tejal Patel

Study Coordinator: Lacey Burey

Phone: 713.441.1159

This is a pilot study is evaluating the effect of hydroxytyrosol, a component of Olive oil, on mammographic density in women at high risk of breast through assessing whether mammographic density is reduced in women at high risk of breast cancer ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Maria Salazar

Phone: 713.441.6011

The primary objective is to evaluate the safety and tolerability of IMMU-132 as a single agent administered in 3-week treatment cycles for up to 8 cycles, in previously treated patients with advanced epithelial cancer. IMMU-132 targets the TROP- ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

Reparixin oral tablets are being tested as a CSC targeting agent in patients with metastatic non- human epidermal growth factor receptor (HER2)-amplified BC. An open label Phase 1b clinical study (REP0111) is ongoing (enrollment completed) in fi ... Read more >

Status: Open Not Enrolling

Investigator: Angel Rodriguez

Study Coordinator: Lacey Burey

Phone: 713.441.1159

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. Aromatase inhibitors, such as anastrozole, letrozole, and exem ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

The purpose of this study is to evaluate the Pathological Complete Response (pCR) of the breast when trastuzumab emtansine (TDM-1) plus Lapatinib plus Abraxane is combined in newly diagnosed HER2 positive breast cancer. ... Read more >

Status: Enrolling

Investigator: Jenny Chang

Study Coordinator: Toniva Boone

Phone: 713.441.0686

This open-label, single-center study will assess the safety and tolerability of combining trastuzumab emtansine (T-DM1) to Lapatinib and Abraxane in patients with metastatic HER2-positive breast cancer. Patients will receive Abraxane on Day 1 of ... Read more >